Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Aoki

Showing results (121-130 of 147) with videos related to

Pageof 15
Sort By:
Respiratory Investigation|November 6, 2025
Familial fibrotic hypersensitivity pneumonitis: A distinct clinical phenotype with shorter leukocyte telomere lengthMasashi Nishimura, Hideya Kitamura, Yoichi Tagami, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 12, 2017
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or OlderKoji Kawamura, Shinichi Kako, Shuichi Mizuta, et al.
Annals of Hematology|March 12, 2019
Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndromeHidehiro Itonaga, Ken Ishiyama, Kazunari Aoki, et al.
American Journal of Hematology|December 15, 2015
Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemiaJun Aoki, Heiwa Kanamori, Masatsugu Tanaka, et al.
Ejhaem|February 23, 2023
Outcomes after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with der(1;7)(q10;p10)Hiroki Mizumaki, Ken Ishiyama, Jun Aoki, et al.
Annals of Hematology|July 21, 2023
Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapyHiroaki Araie, Yasuyuki Arai, Michiko Kida, et al.
Bone Marrow Transplantation|September 7, 2021
Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysisShuhei Kurosawa, Yoshimitsu Shimomura, Hidehiro Itonaga, et al.
Clinical Case Reports|April 10, 2023
EDTA-induced pseudothrombocytopenia in hematopoietic stem cell donorMisato Tsubokura, Minoru Kojima, Saori Nakabayashi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 29, 2019
Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete RemissionTakaaki Konuma, Tadakazu Kondo, Shohei Mizuno, et al.
AAPS Pharmsci|March 21, 2003
Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?Kiyomi Ito, Koji Chiba, Masato Horikawa, et al.
Pageof 15

Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
Respiratory Investigation|November 6, 2025
Familial fibrotic hypersensitivity pneumonitis: A distinct clinical phenotype with shorter leukocyte telomere lengthMasashi Nishimura, Hideya Kitamura, Yoichi Tagami, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 12, 2017
Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or OlderKoji Kawamura, Shinichi Kako, Shuichi Mizuta, et al.
Annals of Hematology|March 12, 2019
Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndromeHidehiro Itonaga, Ken Ishiyama, Kazunari Aoki, et al.
American Journal of Hematology|December 15, 2015
Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemiaJun Aoki, Heiwa Kanamori, Masatsugu Tanaka, et al.
Ejhaem|February 23, 2023
Outcomes after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with der(1;7)(q10;p10)Hiroki Mizumaki, Ken Ishiyama, Jun Aoki, et al.
Annals of Hematology|July 21, 2023
Poor outcome of allogeneic transplantation for therapy-related acute myeloid leukemia induced by prior chemoradiotherapyHiroaki Araie, Yasuyuki Arai, Michiko Kida, et al.
Bone Marrow Transplantation|September 7, 2021
Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysisShuhei Kurosawa, Yoshimitsu Shimomura, Hidehiro Itonaga, et al.
Clinical Case Reports|April 10, 2023
EDTA-induced pseudothrombocytopenia in hematopoietic stem cell donorMisato Tsubokura, Minoru Kojima, Saori Nakabayashi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 29, 2019
Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete RemissionTakaaki Konuma, Tadakazu Kondo, Shohei Mizuno, et al.
AAPS Pharmsci|March 21, 2003
Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?Kiyomi Ito, Koji Chiba, Masato Horikawa, et al.
Pageof 15